back-office Open An Account
partner-with-us Partner with Us
Corporate Actions
Dr Reddys Lab Q2 PAT jumps 14% YoY to Rs 1,437 cr

25-Oct-25   14:17 Hrs IST

Profit before tax (PBT) stood at Rs 1,835 crore in Q2 FY26, down 4.26% year on year.

EBITDA for the quarter stood at Rs 2,351 crore, up 3% as against Rs 2 ,280 crore posted in Q2 FY25.

In its global generics business, North America contributed Rs 3,240.8 crore in revenue, a 13.07% year-on-year decline. Revenue from Europe surged 138.50% to Rs 1,376.2 crore, The India business generated revenue of Rs 1,578 crore, registering an 12.94% YoY.

Revenue from pharmaceutical services and active ingredients (PSAI) came in at Rs 944.99 crore, a 12.40% YoY increase.

In Q2 FY26, the company advanced its global presence through key acquisitions, product launches, and partnerships. It acquired the STUGERON portfolio across 18 APAC and EMEA markets for $50.5 million and launched Colozo (Linaclotide) and PCAB (Tegoprazan) in India.

Globally, it partnered with Unitaid, CHAI, and Wits RHI to make Lenacapavir affordable in 120 countries. Regulatory approvals were secured for Semaglutide in India, the denosumab biosimilar in Europe, and COVA 302 for ALS.

The company integrated two-thirds of its NRT business and launched Sacubitril Valsartan and fluorouracil cream in the US, as well as Skorolox in Russia, underscoring its focus on portfolio expansion and global market growth.

On a half year basis, the company's consolidated net profit rose 7.84% to Rs 2,854.9 crore on 10.58% jump in revenue from operations to Rs 17,350.3 crore in H1 FY26 over H1 FY25.

Commenting on the results, Co-Chairman & MD, G V Prasad said: Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRTJ portfolio, which helped offset the decline in U.S. Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and Pursuing business development initiatives.

Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Shares of Dr Reddys Laboratories rose 0.32% to close at Rs 1,284 on Friday, 24 October 2025.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.